We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CHEMM.CO

Price
671.00
Stock movement down
-15.50 (-2.26%)
Company name
ChemoMetec A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Devices
Markedsverdi
11.68B
Ent verdi
11.49B
Pris/omsetning
56.12
Pris/bok
17.34
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
177.66
Fremtidig P/E
52.29
PEG
-
EPS-vekst
25.80%
1 års avkastning
32.74%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2025-12-16

UTBYTTE

CHEMM.CO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E177.66
Pris til OCF88.27
Pris til FCF98.46
Pris til EBITDA125.43
EV i forhold til EBITDA123.42

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning56.12
Pris til bok17.34
EV i forhold til salg55.22

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall17.40M
EPS (TTM)-
FCF per aksje (TTM)-

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)-
Bruttofortjeneste (TTM)-
Driftsinntekter (TTM)-
Netto inntekt (TTM)-
EPS (TTM)-
EPS (1 år fremover)12.83

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter341.85M
Netto fordringer79.62M
Samlede omløpsmidler543.16M
Goodwill7.35M
Immaterielle eiendeler145.69M
Eiendom, anlegg og utstyr205.97M
Sum eiendeler828.05M
Leverandørgjeld16.08M
Kortsiktig/nåværende langsiktig gjeld0.00
Sum kortsiktig gjeld146.99M
Sum gjeld154.69M
Aksjonærenes egenkapital673.36M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-
Kapitalutgifter (TTM)-
Fri kontantstrøm (TTM)-
Utbetalt utbytte (TTM)-

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-
Avkastning på investert kapital-
Kontantavkastning på investert kapital-

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning674.00
Daglig høy679.50
Daglig lav661.00
Daglig volum33K
Tidenes høyeste1128.00
1 år analytikerestimat-
Beta1.59
EPS (TTM)-
Utbytte per aksje0.00
Ex-div dato15 Oct 2021
Neste dato for resultatpresentasjon4 Feb 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
CHEMM.COS&P500
Nåværende prisfall fra toppnotering-40.51%-1.49%
Høyeste prisfall-68.33%-19.00%
Dato for høyeste fall11 Oct 20248 Apr 2025
Gj.snittlig fall fra topp-51.26%-2.63%
Gj.snittlig tid til ny topp-6 days
Maks tid til ny topp298 days89 days
SELSKAPSOPPLYSNINGER
CHEMM.CO (ChemoMetec A/S) company logo
Markedsverdi
11.68B
Markedsverdi kategori
Large-cap
Beskrivelse
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerod, Denmark.
Ansatte
170
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Denmark
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
ChemoMetec A/S recently reported first-quarter 2025 revenue exceeding forecasts alongside details of new product launches and a planned organizational restructuring. An important development is the co...
12. november 2025
ChemoMetec (CPSE:CHEMM) has been on investors’ watchlists with a sharp upswing in its share price in the past 3 months. The stock is up over 50% during this period and has caught the attention of the ...
11. november 2025
ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions r...
7. november 2025
Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 1...
6. november 2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive tren...
28. oktober 2025
ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At t...
9. oktober 2025
As the European markets navigate a complex landscape of interest rate policies and trade tensions, the pan-European STOXX Europe 600 Index has remained relatively stable, while major stock indexes in ...
2. oktober 2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating pro...
11. september 2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside i...
11. september 2025
As European markets experience a lift, buoyed by hopes of lower U.S. borrowing costs and a surge in business activity, investors are turning their attention to small-cap stocks that might offer unique...
29. august 2025
Neste side